Compare PERI & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | BBNX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Israel | United States |
| Employees | N/A | 423 |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.4M | 493.1M |
| IPO Year | 2005 | N/A |
| Metric | PERI | BBNX |
|---|---|---|
| Price | $10.46 | $9.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $14.50 | ★ $23.80 |
| AVG Volume (30 Days) | 232.3K | ★ 967.6K |
| Earning Date | 05-20-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.98 | $34.90 |
| Revenue Next Year | $2.48 | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.07 | $8.80 |
| 52 Week High | $11.44 | $32.71 |
| Indicator | PERI | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 38.35 |
| Support Level | $9.37 | $8.80 |
| Resistance Level | $10.54 | $11.92 |
| Average True Range (ATR) | 0.33 | 0.55 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 33.47 | 6.11 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.